Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03410056 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03410056 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 36 participants.
The verdict
NCT03410056, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA). Phase 2a. To evaluate the efficacy of Efavaleukin alfa at week 12 as measured by the American College of Rheumatology 20 percent improvement criteria (ACR 20) in adult subjects with moderate to severe RA.
Interventions
- DRUG Placebo
- DRUG Efavaleukin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-05-22 |
| Est. Completion | 2020-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03410056
The ClinicalTrials.gov registry entry for NCT03410056 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03410056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03410056 about?
NCT03410056 is a clinical study titled "Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis". Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA). Phase 2a. To evaluate the efficacy of Efavaleukin alfa at week 12 as measured by the American College of Rheumatology 20 percent improve...
What is the current status of trial NCT03410056?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-05-22. Estimated completion is 2020-05-13.
What interventions are being tested in trial NCT03410056?
The interventions under investigation include: Placebo (DRUG), Efavaleukin alfa (DRUG).
Who is sponsoring clinical trial NCT03410056?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.